Skip to main content
Top
Published in: Clinical and Experimental Nephrology 1/2014

01-02-2014 | Images in Nephrology

Hyponatremia associated with primary central nervous system lymphoma

Authors: Seong Kwon Ma, Kyung-Hwa Lee, Soo Wan Kim

Published in: Clinical and Experimental Nephrology | Issue 1/2014

Login to get access

Excerpt

An 80-year-old man was admitted to the emergency department with general weakness. On admission, his blood pressure was 140/70 mmHg; body temperature, 36.5 °C; pulse rate, 78 beats/min; and respiration rate, 20 breath cycles/min. He was not dehydrated, and did not have edema. The chest radiograph did not show any active lung lesions. The laboratory data were as follows: white blood cell count, 7,500/mm3; hemoglobin, 11.0 g/dL; platelet count, 193,000/mm3; blood urea nitrogen, 33.6 mg/dL; serum creatinine, 1.2 mg/dL; glucose, 126 mg/dL; sodium, 116 mEq/L; potassium, 4.6 mEq/L; chloride, 93 mEq/L; uric acid, 2.7 mg/dL; and serum osmolality, 249 mosmol/kg. There was no abnormal finding on random urinalysis. Urine sodium concentration was 116 mEq/L, and urine potassium concentration was 25.9 mEq/L. Urine osmolality was 592 mosmol/kg. Results of endocrine function tests were as follows: T3, 0.23 ng/mL (reference range, 0.6–1.6 ng/mL); free T4, 0.68 ng/dL (reference range, 0.8–1.54 ng/dL); thyroid-stimulating hormone, 0.155 μU/mL (reference range, 0.55–4.78 μU/mL); cortisol, 2.3 μg/dL (reference range, 3.0–23.0 μg/dL); adrenocorticotropic hormone 13.0 pg/mL (reference range, 6.0–76.0 pg/mL); growth hormone, 0.1 ng/mL (reference range, 0.5–17.0 ng/mL); prolactin, 49.7 ng/mL (reference range, 2.8–29.9 ng/mL); luteinizing hormone, 0.12 U/L (reference range, 3.1–34.6 U/L); follicle-stimulating hormone, 1.11 U/L (reference range, 1.4–18.1 U/L); and free testosterone, 0.08 pg/mL (reference range, 5.6–19.0 pg/mL). Brain magnetic resonance imaging revealed abnormal contrast-enhancing lesions in the hypothalamus, pituitary stalk, optic chiasm, and lateral ventricles of both sides (Fig. 1). Endoscopic brain biopsy was performed.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma. 2008;49(Suppl 1):43–51.PubMedCrossRef Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma. 2008;49(Suppl 1):43–51.PubMedCrossRef
2.
go back to reference Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system non-Hodgkin’s lymphoma. The Massachusetts General Hospital experience 1958–1989. Cancer. 1994;74:1383–97.PubMedCrossRef Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system non-Hodgkin’s lymphoma. The Massachusetts General Hospital experience 1958–1989. Cancer. 1994;74:1383–97.PubMedCrossRef
3.
4.
go back to reference Raftopoulos H. Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer. 2007;15:1341–7.PubMedCrossRef Raftopoulos H. Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer. 2007;15:1341–7.PubMedCrossRef
Metadata
Title
Hyponatremia associated with primary central nervous system lymphoma
Authors
Seong Kwon Ma
Kyung-Hwa Lee
Soo Wan Kim
Publication date
01-02-2014
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 1/2014
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0839-z

Other articles of this Issue 1/2014

Clinical and Experimental Nephrology 1/2014 Go to the issue

Images in Nephrology

Late peritoneal leakage

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine